UBS AM
CGEM icon

UBS AM’s Cullinan Oncology CGEM Stock Holding History

UBS AM’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.53M Buy
84,178
+16,522
+24% +$245K ﹤0.01% 2176
2026
Q1 		$961K Buy
67,656
+19,605
+41% +$252K ﹤0.01% 2354
2025
Q4 		$497K Buy
48,051
+888
+2% +$8.01K ﹤0.01% 2321
2025
Q3 		$280K Sell
47,163
-59,417
-56% -$435K ﹤0.01% 2207
2025
Q2 		$803K Buy
106,580
+26,227
+33% +$211K ﹤0.01% 2432
2025
Q1 		$608K Sell
80,353
-11,439
-12% -$110K ﹤0.01% 2456
2024
Q4 		$1.12M Buy
91,792
+20,881
+29% +$300K ﹤0.01% 2318
2024
Q3 		$1.19M Buy
70,911
+2,377
+3% +$42.2K ﹤0.01% 2310
2024
Q2 		$1.2M Buy
+68,534
New +$1.46M ﹤0.01% 2283

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

UBS AM's CGEM Position: Q2 2026 in Review

UBS AM increased its Cullinan Oncology (CGEM) stake by 24% in Q2 2026, buying an estimated $245K and bringing the position to 84,178 shares worth $1.53M. The position accounts for ﹤0.01% of the portfolio, ranked #2176.

UBS AM first reported a position in CGEM in Q2 2024 and has held it in 9 quarters since. 183 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • UBS AM held 84,178 shares of Cullinan Oncology worth $1.53M as of Q2 2026.
  • UBS AM bought 16,522 Cullinan Oncology shares in Q2 2026, an estimated $245K.
  • Cullinan Oncology made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #2176 holding.
  • UBS AM first reported a position in Cullinan Oncology in Q2 2024 and has held it in 9 quarters since.
  • 183 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.